Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01198067 · OUTCOME

Cycles Completed

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia · Source last updated 2025-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Number of Cycles
Interval / dispersion
Full Range
Time frame
Study Completion (Avg. 1 Year)

What was measured

Length of Treatment

Groups in this outcome

Cohort 2

2mg Pomolidomide per day per Cycle (Cycle = 28 days)

Cohort 3

1mg Pomolidomide per day per Cycle (Cycle = 28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 23
Cohort 36

Reported measurements

Source class 1
Values in Number of Cycles · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Cohort 22Not reported12Not reported
Cohort 37Not reported412Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        2
        value
        2
      2. group Id
        OG001
        lower Limit
        4
        upper Limit
        12
        value
        7
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      6
    units
    Participants
description
Length of Treatment
dispersion Type
Full Range
groups
  1. description
    2mg Pomolidomide per day per Cycle (Cycle = 28 days)
    id
    OG000
    title
    Cohort 2
  2. description
    1mg Pomolidomide per day per Cycle (Cycle = 28 days)
    id
    OG001
    title
    Cohort 3
param Type
MEDIAN
reporting Status
POSTED
time Frame
Study Completion (Avg. 1 Year)
title
Cycles Completed
type
SECONDARY
unit Of Measure
Number of Cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice